AMA. A. Magomedova

A. A. Magomedova

*This is an algorithmically generated author record based on publicly available information.

A. A. Magomedova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of human albumin solutions in adult patients undergoing cardiac surgery

    by D. A. Reznik, D. A. Petrenko, L. V. Selivanova, M. A. Balalaeva, R. D. Komnov, A. A. Eremenko, A. A. Anderzhanova, Yu. A. Melyoshkina, M. I. Tsarev, M. V. Lukina, et al.

    Introduction . Human albumin (HA) solution is commonly used in cardiac surgery for hypovolemia correction, hemodynamic stabilization, and as a component of perfusion media. Despite its widespread use, the efficacy and safety of HA in cardiac surgery patients remain debated. Existing evidence is conflicting: some studies suggest potential benefits for hemodynamic control and renal function, while others show no significant advantage over crystalloids or synthetic colloids regarding key outcomes such as mortality and complication rates. The lack of unified clinical guidelines or algorithms for HA administration in the perioperative period, coupled with its high cost, underscores the need for a systematic review of current evidence to define clear and justified indications for its use in this specific patient population. The objective was to review the literature on the effectiveness and safety of using HA solutions in adult cardiac surgery patients Materials and methods . Based on the analysis of literature in the PubMed, Cochrane Library, eLibrary, Google Scholar databases, publications were selected with search restrictions on the following parameters: «people», «adults», «efficacy», «safety», «replenishment of CBV», «hypoalbuminemia », «intensive care», «surgical intervention», «cardiac surgery», «mortality», «survival». Results . According to the literature analysis, the use of HA solutions in cardiac surgery patients in the situation of hypovolemia correction and hemodynamic stabilization is justified. Preference should be given to isooncotic HA solution (4–5%). The administration of HA solution does not affect the frequency of postoperative complications, mortality, length of stay in the intensive care unit and hospital. Conclusions . The use of HA solutions in cardiac surgery patients requires an individual approach, assessment of the clinical condition and potential benefits of its physiological effects in certain clinical scenarios, however, additional randomized clinical studies comparing albumin 5% and albumin 20% in this population are needed for final conclusions.